← Leaderboards
Ruth Margrit Ruprecht
Dana-Farber Cancer Institute
$54,953,328
Attributed
$54,953,328
Total exposure
77
Grants
55
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.9M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$107,589,863 · 79
By mechanism
P01$54,144,419 · 8
R01$25,505,061 · 8
U19$10,153,460 · 3
R37$7,654,918 · 1
P51$5,086,673 · 51
P30$2,363,240 · 3
Top collaborators
- Sylvain Fleury4 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Ellis L Reinherz$59,058,313
- Lisa A. Cavacini$5,947,978
- Martha K Mann$1,306,670
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaVirusSimian Human Immunodeficiency VirusPrimatesAnimalsTransmission ProcessDoseVaccinesHiv-1MonkeysResourcesResearch PersonnelOralPassive ImmunizationUnited States National Institutes Of HealthFundingInfectionPreventIn VivoCellsProgramsAids VaccinesAntibodiesInstitution
Grant awards (192)
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$1,277,195
U19 · FY2023 · AI · contact PI
Administration$255,527
U19 · FY2023 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,615,853
U19 · FY2022 · AI · contact PI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$279,725
U19 · FY2022 · AI · contact PI
Administration$149,324
U19 · FY2022 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,719,534
U19 · FY2021 · AI · contact PI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$507,591
U19 · FY2021 · AI · contact PI
Administration$134,148
U19 · FY2021 · AI · contact PI
Defense-in-depth against mucosal HIV clade C invasion$3,519,079
P01 · FY2020 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$1,855,534
U19 · FY2020 · AI · contact PI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$655,586
U19 · FY2020 · AI · contact PI
Harnessing humoral immunity against HIV clade C$392,580
P01 · FY2020 · AI · contact PI
Administration$261,194
U19 · FY2020 · AI · contact PI
Administration$177,440
P01 · FY2020 · AI · contact PI
Defense-in-depth against mucosal HIV clade C invasion$4,400,187
P01 · FY2019 · AI · contact PI
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels$727,169
U19 · FY2019 · AI · contact PI
Harnessing humoral immunity against HIV clade C$385,133
P01 · FY2019 · AI · contact PI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$369,510
U19 · FY2019 · AI · contact PI
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model$221,478
U19 · FY2019 · AI · contact PI
Administration$182,187
P01 · FY2019 · AI · contact PI
Administration$66,149
U19 · FY2019 · AI · contact PI
Administration$57,943
U19 · FY2019 · AI · contact PI
Defense-in-depth against mucosal HIV clade C invasion$4,923,836
P01 · FY2018 · AI · contact PI
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates$1,255,405
R01 · FY2018 · AI · contact PI
Harnessing humoral immunity against HIV clade C$459,348
P01 · FY2018 · AI · contact PI
Administration$219,472
P01 · FY2018 · AI · contact PI
Defense-in-depth against mucosal HIV clade C invasion$5,134,226
P01 · FY2017 · AI · contact PI
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates$1,255,405
R01 · FY2017 · AI · contact PI
Harnessing humoral immunity against HIV clade C$502,476
P01 · FY2017 · AI · contact PI
Administration$214,813
P01 · FY2017 · AI · contact PI
Defense-in-depth against mucosal HIV clade C invasion$4,095,518
P01 · FY2016 · AI · contact PI
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates$1,255,405
R01 · FY2016 · AI · contact PI
Humoral Correlates of Protection Against HIV$775,917
R01 · FY2016 · AI · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$738,148
R01 · FY2016 · DE · contact PI
Harnessing humoral immunity against HIV clade C$467,256
P01 · FY2016 · AI · contact PI
Administration$170,137
P01 · FY2016 · AI · contact PI
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates$1,255,405
R01 · FY2015 · AI · contact PI
Humoral Correlates of Protection Against HIV$824,344
R01 · FY2015 · AI · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$757,018
R01 · FY2015 · DE · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$951,220
R01 · FY2014 · DE · contact PI
Humoral Correlates of Protection Against HIV$799,742
R01 · FY2014 · AI · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$1,119,362
R01 · FY2013 · DE · contact PI
Optimized Adaptation of Simian-tropic R5 HIV Clade C to Pig-tailed Macaques$903,811
R56 · FY2013 · AI · contact PI
Humoral Correlates of Protection Against HIV$701,822
R01 · FY2013 · AI · contact PI
Small Animal Containment$302,698
P30 · FY2013 · AI · contact PI
Humoral Correlates of Protection Against HIV$71,250
R01 · FY2013 · AI · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$48,600
R01 · FY2013 · DE · contact PI
Humoral Correlates of Protection Against HIV$855,955
R01 · FY2012 · AI · contact PI
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?$843,374
R01 · FY2012 · DE · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$759,922
R37 · FY2012 · AI · contact PI
Small Animal Containment$324,721
P30 · FY2012 · AI · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$45,964
R37 · FY2012 · AI · contact PI
Vaccination against mucosal HIV clade C transmission$2,033,575
P01 · FY2011 · AI · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$805,886
R37 · FY2011 · AI · contact PI
Vaccination against mucosal HIV clade C transmission$510,102
P01 · FY2011 · AI · contact PI
Small Animal Containment$440,851
P30 · FY2011 · AI · contact PI
Harnessing Humoral Immunity against HIV Clade C$392,832
P01 · FY2011 · AI · contact PI
Molecular Biology$242,808
P01 · FY2011 · AI · contact PI
Administrative Core$159,782
P01 · FY2011 · AI · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$59,500
P51 · FY2011 · RR · contact PI
NEUTRALIZING ANTIBODY COVERAGE FOR CTL VACCINES (PROJECT 2)$59,500
P51 · FY2011 · RR · contact PI
HIV-1 MICROGLIAL TROPISM AND NEUROVIRULENCE$59,500
P51 · FY2011 · RR · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$59,500
P51 · FY2011 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$59,500
P51 · FY2011 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$59,500
P51 · FY2011 · RR · contact PI
Vaccination against mucosal HIV clade C transmission$2,199,333
P01 · FY2010 · AI · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$814,028
R37 · FY2010 · AI · contact PI
Harnessing Humoral Immunity against HIV Clade C$335,454
P01 · FY2010 · AI · contact PI
Small Animal Containment$332,239
P30 · FY2010 · AI · contact PI
Molecular Biology$210,918
P01 · FY2010 · AI · contact PI
Administrative Core$132,656
P01 · FY2010 · AI · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$43,862
P51 · FY2010 · RR · contact PI
NEUTRALIZING ANTIBODY COVERAGE FOR CTL VACCINES (PROJECT 2)$43,862
P51 · FY2010 · RR · contact PI
HIV-1 MICROGLIAL TROPISM AND NEUROVIRULENCE$43,862
P51 · FY2010 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$43,862
P51 · FY2010 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$43,862
P51 · FY2010 · RR · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$43,862
P51 · FY2010 · RR · contact PI
Vaccination against mucosal HIV clade C transmission$2,955,315
P01 · FY2009 · AI · contact PI
Vaccination against mucosal HIV clade C transmission$1,974,218
P01 · FY2009 · AI · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$822,250
R37 · FY2009 · AI · contact PI
Harnessing Humoral Immunity against HIV Clade C$409,408
P01 · FY2009 · AI · contact PI
Attenuated listeria vectors as an AIDS vaccine in macaques$344,398
P01 · FY2009 · AI · contact PI
Small Animal Containment$322,517
P30 · FY2009 · AI · contact PI
HIV-1 Env Microglial Tropism and Neurovirulence$259,080
R21 · FY2009 · NS · contact PI
Molecular Biology$256,551
P01 · FY2009 · AI · contact PI
Administrative Core$162,253
P01 · FY2009 · AI · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$68,028
P51 · FY2009 · RR · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$68,028
P51 · FY2009 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$68,028
P51 · FY2009 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$68,028
P51 · FY2009 · RR · contact PI
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$68,028
P51 · FY2009 · RR · contact PI
HIV-1 MICROGLIAL TROPISM AND NEUROVIRULENCE$56,690
P51 · FY2009 · RR · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$24,608
R37 · FY2009 · AI · contact PI
Vaccination against mucosal HIV clade C transmission$2,264,811
P01 · FY2008 · AI · contact PI
Infant Immunoprophylaxis against a Primate Lentivirus$820,779
R37 · FY2008 · AI · contact PI
Molecular evolution of multiply deleted SIV in vivo$710,944
R01 · FY2008 · RR · contact PI
Harnessing Humoral Immunity against HIV Clade C$319,819
P01 · FY2008 · AI · contact PI
HIV-1 Env Microglial Tropism and Neurovirulence$215,780
R21 · FY2008 · NS · contact PI
Molecular Biology$189,523
P01 · FY2008 · AI · contact PI
Core--Small Animal Containment Facility$154,917
P30 · FY2008 · AI · contact PI
Administrative Core$129,323
P01 · FY2008 · AI · contact PI
MECHANISMS OF ORAL SIV TRANSMISSION$81,625
P51 · FY2008 · RR · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$81,625
P51 · FY2008 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$81,625
P51 · FY2008 · RR · contact PI
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$81,625
P51 · FY2008 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$81,625
P51 · FY2008 · RR · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$81,625
P51 · FY2008 · RR · contact PI
Vaccination against mucosal HIV clade C transmission$2,163,226
P01 · FY2007 · AI · contact PI
Molecular evolution of multiply deleted SIV in vivo$726,161
R01 · FY2007 · RR · contact PI
Infant immunoprophylaxis against a primate lentivirus$704,456
R37 · FY2007 · AI · contact PI
SHIV Transmission Through Oral Versus Other Mucosae$617,859
R01 · FY2007 · DE · contact PI
Harnessing Humoral Immunity against HIV Clade C$317,548
P01 · FY2007 · AI · contact PI
Core--Small Animal Containment Facility$150,795
P30 · FY2007 · AI · contact PI
Administrative Support$137,452
P01 · FY2007 · AI · contact PI
MECHANISMS OF ORAL SIV TRANSMISSION$78,544
P51 · FY2007 · RR · contact PI
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$78,544
P51 · FY2007 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$78,544
P51 · FY2007 · RR · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$78,544
P51 · FY2007 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$65,453
P51 · FY2007 · RR · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$65,453
P51 · FY2007 · RR · contact PI
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$1,150,724
P01 · FY2006 · AI · contact PI
Molecular evolution of multiply deleted SIV in vivo$745,199
R01 · FY2006 · RR · contact PI
Infant immunoprophylaxis against a primate lentivirus$680,808
R37 · FY2006 · AI · contact PI
SHIV Transmission Through Oral Versus Other Mucosae$636,768
R01 · FY2006 · DE · contact PI
Core--Small Animal Containment Facility$146,469
P30 · FY2006 · AI · contact PI
MECHANISMS OF ORAL SIV TRANSMISSION$119,236
P51 · FY2006 · RR · contact PI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$119,236
P51 · FY2006 · RR · contact PI
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$59,665
P51 · FY2006 · RR · contact PI
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$59,665
P51 · FY2006 · RR · contact PI
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$59,665
P51 · FY2006 · RR · contact PI
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$59,665
P51 · FY2006 · RR · contact PI
HIV Vaccines$30,000
R13 · FY2006 · AI · contact PI
Dynamics of SHIV clade C and S mansoni coinfection$776,361
R56 · FY2005 · AI
Infant immunoprophylaxis against a primate lentivirus$768,135
R37 · FY2005 · AI
Molecular evolution of multiply deleted SIV in vivo$722,063
R01 · FY2005 · RR
SHIV Transmission Through Oral Versus Other Mucosae$652,156
R01 · FY2005 · DE
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$92,728
P51 · FY2005 · RR
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$92,728
P51 · FY2005 · RR
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$92,728
P51 · FY2005 · RR
MECHANISMS OF ORAL SIV TRANSMISSION$92,204
P51 · FY2005 · RR
SHIV TRANSMISSION THROUGH ORAL VS OTHER MUCOSAE$52,438
P51 · FY2005 · RR
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$52,438
P51 · FY2005 · RR
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$1,869,242
P01 · FY2004 · AI
Infant immunoprophylaxis against a primate lentivirus$689,455
R37 · FY2004 · AI
SHIV Transmission Through Oral Versus Other Mucosae$655,597
R01 · FY2004 · DE
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$91,436
P51 · FY2004 · RR
VACCINATION AGAINST INTRAPARTUM HIV1 CLADEC TRANSMISSION$91,436
P51 · FY2004 · RR
MOLECULAR EVOLUTION OF MULTIPLE DELETED SIV IN VIVO$91,436
P51 · FY2004 · RR
MECHANISMS OF ORAL SIV TRANSMISSION$90,941
P51 · FY2004 · RR
ATTENUATED RECOMBINANT LISTERIA AS ORAL AIDS VACCINE$51,707
P51 · FY2004 · RR
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$46,107
P01 · FY2004 · AI
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$1,966,903
P01 · FY2003 · AI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$739,280
R01 · FY2003 · RR
Infant immunoprophylaxis against a primate lentivirus$718,627
R37 · FY2003 · AI
Attenuated recombinant Listeria as oral AIDS vaccine$497,060
R21 · FY2003 · AI
MECHANISMS OF ORAL SIV TRANSMISSION$386,329
R01 · FY2003 · DE
FETAL IMMUNOPROPHYLAXIS AGAINST PRIMATE LENTIVIRUS$87,240
P51 · FY2003 · RR
MECHANISMS OF ORAL SIV TRANSMISSION$83,876
P51 · FY2003 · RR
TOWARDS AN ORAL AIDS VACCINE$83,876
P51 · FY2003 · RR
VACCINATION AGAINST INTRAPARTUM HIV-1 CLADE C TRANSMISSION$83,876
P51 · FY2003 · RR
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$83,876
P51 · FY2003 · RR
INFANT IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$83,876
P51 · FY2003 · RR
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$2,248,304
P01 · FY2002 · AI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$729,379
R01 · FY2002 · RR
MECHANISMS OF ORAL SIV TRANSMISSION$366,858
R01 · FY2002 · DE
LENTIVIRUS INFECTION OF NEONATAL DENDRITIC CELLS$357,793
R01 · FY2002 · AI
VACCINATION AGAINST MUCOSAL SIV INFECTION IN NEONATES$209,143
P51 · FY2002 · RR
FETAL IMMUNOPROPHYLAXIS AGAINST PRIMATE LENTIVIRUS$209,143
P51 · FY2002 · RR
IMMUNOTHERAPY OF CONGENITAL SIV INFECTION$209,143
P51 · FY2002 · RR
REV INDEPENDENT SIVMAC239 INFECTION IN NEWBORN MACAQUES$209,143
P51 · FY2002 · RR
Passive immunization with synergistic human mAbs$171,469
P01 · FY2002 · AI
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$23,848
P01 · FY2002 · AI
CORE--ANIMAL BIOHAZARD FACILITY$0
P30 · FY2002 · AI
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$2,111,611
P01 · FY2001 · AI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$700,300
R01 · FY2001 · RR
FETAL IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$598,540
R01 · FY2001 · AI
MECHANISMS OF ORAL SIV TRANSMISSION$368,795
R01 · FY2001 · DE
LENTIVIRUS INFECTION OF NEONATAL DENDRITIC CELLS$348,876
R01 · FY2001 · AI
Passive immunization with synergistic human mAbs$171,469
P01 · FY2001 · AI
CORE--ANIMAL BIOHAZARD FACILITY$0
P30 · FY2001 · AI
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION$1,128,280
P01 · FY2000 · AI
MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO$681,654
R01 · FY2000 · RR
FETAL IMMUNOPROPHYLAXIS AGAINST A PRIMATE LENTIVIRUS$551,429
R01 · FY2000 · AI
MECHANISMS OF ORAL SIV TRANSMISSION$360,492
R01 · FY2000 · DE
LENTIVIRUS INFECTION OF NEONATAL DENDRITIC CELLS$340,217
R01 · FY2000 · AI
CORE--ANIMAL BIOHAZARD FACILITY$188,033
P30 · FY2000 · AI
Passive immunization with synergistic human mAbs$171,469
P01 · FY2000 · AI
IMMUNOTHERAPY OF CONGENITAL SIV INFECTION$84,459
P51 · FY2000 · RR
FETAL IMMUNOPROPHYLAXIS AGAINST PRIMATE LENTIVIRUS$84,459
P51 · FY2000 · RR
REV INDEPENDENT SIVMAC239 INFECTION IN NEWBORN MACAQUES$84,459
P51 · FY2000 · RR
VACCINATION AGAINST MUCOSAL SIV INFECTION IN NEONATES$84,459
P51 · FY2000 · RR
SIV &HIV PATHOGENESIS DURING ONTOGENY$84,459
P51 · FY2000 · RR